Table 2 Summary of studies on the reproduction number of the alpha variant
Study | Location | Study date | Method | Estimated R0 | Other findings |
|---|---|---|---|---|---|
Curran et al. | UK | August, 2020 to December, 2020 | Rapid scoping review approach | Transmissibility: 52% (95% CI 46, 58) higher than the other variants Growth rate: 71% (95% CI 65–75%) higher than the other variants | |
Grabowski et al. | UK | October, 2020 to December, 2020 | Based on GISAID data available and Genome Sequence Analysis | Replicative advantage of B.1.1.7 over 20A.EU1: 1.83–2.18 (95% CI 1.71–2.40) Replicative advantage of B.1.1.7 over other strains: 2.03–2.47 (95% CI1.89–2.77) | |
Hunter et al. | UK | October, 2020 to December, 2020 | R for preceding days was obtained by summing all reports of new COVID infections for each day and the previous six days. This was then compared with the sum of new cases over the previous 7-day period | Rt value for B.1.1.7: 1.3, 1.3 and 1.1 Rt value for other strains: 0.92, 0.91 and 0.97 In England, London and South East regions | |
Davies et al. | UK | March, 2020 to December, 2020 | Using a time-varying multinomial spline model | Increased growth rate of + 0.104 day–1 [95% CI 0.100 to 0.108] relative to the previous variant 77% (95% CI 73 to 81%) higher R value | |
Washington et al. | US | December 2020 to January 2021 | SARS-CoV-2 sequencing and Phylogenetic analyses | 35–46% increased transmissibility | |
Sheikhi et al. | Iran | April, 2021 to April, 2021 | EGR, ML, SB, and SIR models | R0: 2.26–11.38 using statistical models 12.13 by time-dependent SIR model (in the time interval with exponential growth) |